Sensome Raises Funds to Begin Clinical Development of Microsensor Stroke Guidewire Technology


July 17, 2017—Sensome, formerly Instent, announced that it has completed a €4.7 million financing round to bring its first product to clinical trials. Sensome is developing microsensor technology for smart medical devices. This financing will allow the company to prepare first-in-human testing of its neurovascular device in 2018.

According to the company, Sensome’s sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body with machine learning algorithms for accurate and predictive real-time analysis.

Sensome’s first product integrates its technology with a guidewire for the treatment of ischemic stroke. The company's connected stroke guidewire will help select the fastest device to reopen the vessel for each patient. Depending on the composition of the blood clot, the choice of tool to remove the clot significantly impacts the time to reopen the artery, ranging from minutes to hours, noted the company.

Sensome operates out of Ecole Polytechnique in Palaiseau, France. CEO Franz Bozsak cofounded Sensome with Abdul Barakat, PhD, Professor at the Hydrodynamics Laboratory at Ecole Polytechnique. Venture capital firm Kurma Diagnostics led a syndicate with the new Paris-Saclay Seed Fund and ID Invest, as well as other investors.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.